A study using rosiglitazone (RGZ), a PPAR-γ agonist, showed that RGZ was capable of activating the AMPK pathway, leading to enhanced autophagy, reactive oxygen species formation, as well as upregulating beclin-1 and LAMP-1, a protein involved in the process of autophagy to induce autophagic cell death in ACC cell lines [37]. Here, LAMP1 is linked to adrenal cortex carcinoma.